D-0921-2017 Class II Terminated
FDA drug recall D-0921-2017 was initiated by Lucid Pharma LLC on Jun 1, 2017 and is designated Class II. Reason for recall: Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules. The recall status is terminated (terminated Sep 25, 2019). Affected quantity: a) 44168 bottles; b) 24960 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 28, 2017
- Initiation Date
- Jun 1, 2017
- Termination Date
- Sep 25, 2019
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 44168 bottles; b) 24960 bottles
Product description
Venlafaxine Hydrochloride Extended-Release Capsules USP, 75 mg, packaged in a) 30-count bottles (NDC 52343-132-30) and b) 90-count bottles (NDC 52343-132-90), Rx only, Distributed by: Lucid Pharma LLC, 2 Tower Center Blvd, Suite-1101-B, East Brunswick, NJ 08816 USA.
Reason for recall
Failed Tablet/Capsules Specifications: pharmacists complaints for bottles containing melted capsules.
Distribution pattern
Nationwide in the USA
Code information
Lot #: a) V17516045-A, Exp 08/18; b) V17516047-A 09/18
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0921-2017
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026